Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rationalization of antibiotic therapy in diabetic foot infection and impact on intestinal microbiota
2019-001997-27Phase 4Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Jun 2019
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ceftazidime and amoxicillin + clavulanate in diabetic foot infection (DFI) and bacterial disease (4 arms), sponsored by Institute for Clinical and Experimental Medicine. Started Jun 2019; status: completed.
02
Drugs
ceftazidimeamoxicillin + clavulanate
03
Conditions
diabetic foot infection (DFI)bacterial disease
Beyond the preview
Go deeper on 2019-001997-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001997-27.